<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145377</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00059690</org_study_id>
    <nct_id>NCT02145377</nct_id>
  </id_info>
  <brief_title>PXVX0200 (CVD103-HgR) vs Shanchol in Mali</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol™ Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PaxVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shantha Biotechnics Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the ability of a single dose of PXVX0200 at two different dose levels, to placebo
      to elicit a significant antibody response 14 days after vaccination, compared to baseline.

      To compare the ability of a single dose of PXVX0200 to a comparator vaccine Shanchol, a two
      dose administration, to elicit antibody response by 14 days after vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently there are two licensed inactivated vibrio oral vaccines (Dukoral® [Crucell; Leiden,
      The Netherlands] and Shanchol™ [Shantha Biotechnics; Hyderabad, India]) that are
      pre-qualified by the World Health Organization (WHO) for procurement by United Nations (UN)
      agencies. Each of these vaccines requires a two-dose regimen which is difficult to implement
      in the face of explosive outbreaks of cholera in unsettled situations in developing
      countries. For this reason there is great interest in identifying a cholera vaccine that can
      provide rapid onset of protection following the ingestion of just a single oral dose.

      This Phase 2 randomized, observer-blinded and subject-blinded clinical trial to be conducted
      in Bamako, Mali will assess the immunogenicity of the 10^8 cfu versus the 10^9 cfu
      formulation of PaxVax-manufactured CVD 103-HgR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To elicit a significant rise in serum Inaba vibriocidal antibody after a single vaccination</measure>
    <time_frame>14 days</time_frame>
    <description>A comparison of the ability of a single ≥2 x10E9 cfu oral dose versus a single ≥2 x10E8 cfu oral dose of PXVX0200 (CVD 103-HgR) versus placebo to elicit a significant (&gt; 4-fold) rise in serum Inaba vibriocidal antibody 14 days after vaccination, compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure antibody response for a 10E8 dose and 10E9 dose of PXVX0200 oral vaccine</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the ability of a single ≥2 x108 cfu dose of PXVX0200 (CVD 103-HgR) or ≥2 x109 oral dose of PXVX0200 (CVD 103-HgR) versus Shanchol™ to elicit serum Inaba vibriocidal antibody mean fold rise (compared to baseline titer) and GMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To plot the kinetics of the serum Inaba Vibriocidal antibody response</measure>
    <time_frame>Baseline and post-vaccination time point.</time_frame>
    <description>To plot the kinetics of the serum Inaba vibriocidal antibody response after ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing ≥2 x10E8 cfu or ≥2 x10E9 cfu versus Shanchol™. (With GMT on the Y axis and time points on the X axis, the GMTs at baseline and at each post-vaccination time point will be connected as a line graph).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess fecal shedding of PXVX0200</measure>
    <time_frame>Day 1-3, day 7 and day 14</time_frame>
    <description>Shedding of CVD 103-HgR in stool as determined by stool culture (whole specimen or rectal swab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare rate of diarrhea</measure>
    <time_frame>7 days</time_frame>
    <description>To compare the rate of diarrhea (≥ 4 loose stools within 24 hours) following administration of each vaccine regimen versus placebo over 7 days of follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plot seroconversion</measure>
    <time_frame>Day 7, 14, 21, 28, 35 and 42</time_frame>
    <description>To plot the seroconversion (≥ 4-fold increase over baseline), mean fold rise (comparing baseline titer with post-vaccination titer), and kinetics of serum IgG cholera antitoxin antibody following the ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing ≥2 x10E8 cfu or ≥2 x10E9 cfu versus Shanchol™.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess reactogenicity</measure>
    <time_frame>For seven days after each dose of PXVX0200</time_frame>
    <description>Assess tiredness, vomiting, loss of appetite, abdominal pain and headache</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cholera</condition>
  <arm_group>
    <arm_group_label>PXVX0200 10E8 then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXVX0200 10E8 on day 0; Placebo on day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then PXVX0200 10E8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo on day 0; PXVX0200 10E8 on day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXVX0200 10E9 then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXVX0200 10E9 on day 0; Placebo on day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then PXVX0200 10E9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo on day 0; PXVX0200 10E9 on day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shanchol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two doses of Shanchol, on day 0 and day 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200 10E8</intervention_name>
    <description>Oral dose of PXVX0200 10E8</description>
    <arm_group_label>PXVX0200 10E8 then placebo</arm_group_label>
    <arm_group_label>Placebo, then PXVX0200 10E8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200 10E9</intervention_name>
    <description>Oral dose of PXVX0200 10E9</description>
    <arm_group_label>PXVX0200 10E9 then Placebo</arm_group_label>
    <arm_group_label>Placebo then PXVX0200 10E9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose of sodium bicarbonate buffer</description>
    <arm_group_label>PXVX0200 10E8 then placebo</arm_group_label>
    <arm_group_label>Placebo, then PXVX0200 10E8</arm_group_label>
    <arm_group_label>PXVX0200 10E9 then Placebo</arm_group_label>
    <arm_group_label>Placebo then PXVX0200 10E9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shanchol</intervention_name>
    <description>Licensed comparator</description>
    <arm_group_label>Shanchol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand the study and give consent (either written or through a process
             that involves audio tapes explaining all aspects of the study and the consent form in
             local languages [Bambara and French] followed by making a mark and signature by a
             literate witness)

          -  Healthy men or women, age 18 to 45 years (inclusive) without significant medical
             history

          -  Women of child-bearing potential must have negative urine pregnancy test at baseline,
             prior to vaccination. They must also be willing to use adequate birth control for the
             duration of the 28-day study and have additional pregnancy tests if indicated.
             Effective methods of birth control for this study include abstinence, intrauterine
             device (IUD), oral or depot contraceptive, or barrier plus spermicide

          -  Willingness to remain in the study area until at least 42 days after receipt of the
             first vaccine dose

        Exclusion Criteria:

          -  Health care workers who have direct contact with patients who are immune deficient,
             HIV-positive, or have an unstable medical condition

          -  Clinically significant history of immunodeficiency, cardiovascular disease,
             respiratory disease, endocrine disorder, liver disease, renal disease,
             gastrointestinal disease, neurologic illness, psychiatric disorder requiring
             hospitalization, current drug or alcohol abuse

          -  History of an abnormal stool pattern or regular use of laxatives

          -  Previously received a licensed or investigational cholera vaccine

          -  History of cholera illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milagritos D Tapia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samba O Sow, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre pour le Developpement des Vaccins - Mali</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre pour le Développement des Vaccins, Mali (CVD-Mali)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Milagritos Tapia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cholera</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Mali</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

